The new year greeted Repligen Corp. with disappointing data from its Phase III trial of synthetic human secretin in autism. (BioWorld Today)

In a move to launch its second product in the U.S., ILEX Oncology Inc. filed the first part of a rolling new drug application on Wednesday for Clofarabine to treat refractory or relapsed acute leukemia in children.(BioWorld Today)